A three-phase study designed to test the efficacy, tolerability and safety of the combination of ziprasidone with selective serotonin reuptake inhibitors (SSRI) for patients with major depressive disorder (MDD) that do not sufficiently respond to treatment with SSRIs.

Trial Profile

A three-phase study designed to test the efficacy, tolerability and safety of the combination of ziprasidone with selective serotonin reuptake inhibitors (SSRI) for patients with major depressive disorder (MDD) that do not sufficiently respond to treatment with SSRIs.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2015

At a glance

  • Drugs Ziprasidone (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 03 May 2013 Lead trial centres amended as reported by ClinicalTrials.gov.
    • 03 May 2013 Planned End Date changed from 1 Mar 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top